Sciensus, previously known as Healthcare at Home, is a provider of out-of-hospital healthcare, this can be at home, at work, or in the community. It operates through working with three kinds of provider: public, pharmaceutical companies, and private companies. It employs 1700 staff throughout the UK, including more than 500 clinicians across the UK. The company supports in excess of 200,000 patients every year across 49 therapy areas and 450 chemotherapy regimes.


In July 2021 the company underwent a rebrand - changing its name to Sciensus - which according to the company better reflects its "forward-thinking approach, which aims to harness new digital technology and patient insight to provide patients with more knowledge, more choice and greater convenience."

Sciensus, as Healthcare at Home, began as a supplier of pharmaceutical products to patients in their own homes. In 2013 Healthcare at Home took over the business of drug delivery company, Medco Health Solutions when it pulled out of the UK market. The company has evolved to carry out more than just drug delivery.

The company's strategy is to capitalise off the growing market for intermediate/complex care. This strategy is twofold: to further develop existing expertise in providing medication-related home health care services; and to expand provision of large-scale, clinically-lead services to the NHS and private sector. Their strategic report specifically points out how “the pressure on public finances and the drive to move patient care towards the community setting are both continuing”, which puts them in a secure position.

They work with 48 pharmaceutical companies to provide their products to the 98,000 patients they support. With private providers they act as a subcontractor to directly provide clinical services to patients including: physiotherapy, occupational health, chemotherapy, IV antibiotics, enteral feeding, and palliative care.


According to the latest filed accounts at Companies House, Healthcare at Home reported revenue for the year to October 2019 of £1.35 billion (2018 £1.82 billion), resulting in a gross profit of £101.1 million (2018: £94.9 million), and net profit of almost £13.5 million up from £10.1 million in 2018.


Healthcare at Home is a subsidiary of Halcyon Topco. Over 75% of Halcyon’s shares, however, are owned by Vitruvian Partners Llp, a European private equity firm.


Healthcare at Home is on the NHS Framework agreements for Pharmacy Dispensing and Delivery Services and for Home Delivery of Intravenous and Subcutaneous Immunoglobulin. The company is the leading deliverer of pharmaceutical products to NHS patients at home.

Pharmacy Homecare Services

In June 2017, the Royal Devon and Exeter NHS Foundation Trust commissioned two contracts for pharmacy homecare services: one for "high tech", worth £22,000,000; and one for "mid and low tech", worth £200,500,000. Out of the total £222,500,000, Healthcare at Home received £211,400,000.


In 2021 Healthcare at Home's services were rated "inadequate" and the service was placed in special measures. A report by the CQC found that patients had come to avoidable harm after the company had failed to deliver thousands of medicine prescriptions. The report published in May 2021 said that inspectors found more than 10,000 patients missed a dose of their medicine between October and December 2020 due to problems caused by the introduction of a new information system. Reviews have found some suffered avoidable harm as a result.

The report added: “Some patients’ conditions deteriorated and they had to be admitted to hospital, whilst others experienced psychological trauma because of the uncertainty of not knowing when they would receive their essential medicines.”

Between April and October 2020 there were more than 13,000 incidents involving a missed dose of medicine. The CQC said not all of these resulted in patient harm or were attributed to the provider, but the provider was unable to demonstrate all of the patients had been reviewed.

In 2014 Healthcare at Home was bombarded with complaints over its home delivery of essential prescriptions to NHS patients.  The largest issue was its failure to deliver all medications - some life-saving - on time. Problems emerged after Healthcare at Home switched from using an in-house delivery service to Movianto: an American logistics firm operating throughout Europe. When Movianto’s IT systems failed many patients were left without deliveries. The company was investigated by the regulator.

Delivery issues appeared again in 2017, with patients not receiving vital medicines and phone calls not being returned.


Sign up for the latest stories and investigations

Something went wrong. Please check your entries and try again.